EANS-News: DEWB investment holding NOXXON Pharma AG raises EUR33 million in Series D Round

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information

Berlin, Germany, May 27, 2010 (euro adhoc) - NOXXON Pharma AG
(NOXXON), a company focused on the development of mirror image
oligonucleotide therapeutics called Spiegelmers®, announced today the
successful closing of a EUR33 million Series D round of financing.
The round was led by new investor, NGN Capital, and joined by
existing investors TVM Capital, Sofinnova Partners, Edmond de
Rothschild Investment Partners, Seventure Partners, VC Fonds
Technologie Berlin GmbH, Dow Venture Capital, FCP OP MEDICAL
BioHealth-Trends, IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH,
the Dieckell Group, and others.

The funds raised will be used primarily for the ongoing clinical and
pre-clinical development of NOXXON´s lead products NOX-E36, NOX-A12,
and NOX-H94 in the fields of diabetic complications, oncology and
hematology. These products are high-potency inhibitors of their
respective targets, generated with NOXXON´s proprietary Spiegelmer®
technology. Spiegelmers® are marked by their biostability and an
extremely low potential for toxic or immunogenic side effects.

"This investment provides NOXXON with the funds to advance the
clinical development of our three most advanced in-house programs
without the need for additional external support. NGN´s decision to
lead this round is a testament to the value of the Spiegelmer®
technology and the commercial potential of the development programs
pursued by NOXXON." stated NOXXON´s CEO Dr. Frank Morich.

Peter Johann, a Managing General Partner at NGN Capital, commented:
"We are very excited about NOXXON´s platform and the product
opportunities which can be created from it. The Company and its
experienced management team made significant progress over the last
years bringing two Spiegelmers® into the clinic and one more close to
clinical development. With the funding NOXXON will be able to further
clinically validate their technology and achieve clinical proof of
efficacy with the lead compounds." Dr. Johann will join the Board of
NOXXON.

About NOXXON Berlin-based NOXXON Pharma AG is a clinical stage
biotechnology company focusing on the development of Spiegelmers® for
the treatment of various disease indications. NOXXON is in possession
of a broad patent estate and has access to a readily scalable GMP
production. In addition to its in-house programs, NOXXON discovers
and develops Spiegelmers® in collaboration with partners from the
pharmaceutical industry, including Eli Lilly and Hoffmann La-Roche.
The business strategy of NOXXON is to broaden this range of
collaborations through co-development and licensing agreements for
the proprietary clinical and pre-clinical products. Currently, the
company has two compounds in clinical development. The declared goal
of NOXXON is to establish its oligonucleotide-based drug discovery
platform (Spiegelmers®) as the leading "scaffold" technology to
create new chemical entities with superior properties.

About NGN Capital NGN Capital is a venture capital firm dedicated to
healthcare investing, focusing on ventures with the potential to
achieve above average private equity returns with an emphasis on
later stage investments. The funds have flexibility to invest in a
broad cross section of healthcare and biotechnology segments
including drug products, medical devices and other healthcare
segments like services. The funds are diversified by stage, from
later stage to selected early stage opportunities, as well as by
geography by investing predominantly in the US and in Europe. NGN
Capital's North American offices are in New York, NY, Greenwich, CT
and its European office is in Heidelberg, Germany

About TVM Capital The TVM Capital Life Science & Healthcare Practice
currently manages committed capital of about 860 million Euros
($1.13bn) for investments in the life science and healthcare sectors
from headquarters in Munich, an office in Boston and a representation
in Singapore. The two sector teams build on the expertise,
experience, international approach and demonstrated success of 113
investments and more than 70 exits including 37 initial public
offerings of portfolio companies on Nasdaq, and the London,
Frankfurt, Zurich and Vienna Stock Exchanges, and 24 trade sales.
This track record of successful investing and value creation, in
traditional early and late-stage life science venture as well as
healthcare private equity, make the TVM Capital Life Science &
Healthcare Practice a preferred partner for ambitiously growing
companies in our target sectors. The operating entity of the TVM
Capital Healthcare Private Equity activities in the Middle East and
Northern Africa (MENA) is TVM Capital MENA Ltd. based at the Dubai
International Financial Center (DIFC), Dubai, United Arab Emirates.
The firm operates the region's first Shari'a compliant and dedicated
healthcare and pharmaceutical investment fund. The fund is regulated
by the Dubai Financial Services Authority (DFSA).

About Sofinnova Partners Sofinnova Partners is an independent venture
capital firm based in Paris, France. For over 35 years, the firm has
backed nearly 500 companies at different stages of development - pure
creations, spin-offs, as well as turnaround situations - and worked
alongside Europe´s key entrepreneurs in the technology, life sciences
and cleantech sectors. With EUR1.1 billion of funds under
management, Sofinnova Partners´ experienced team and hands-on
approach in building portfolio companies through to exit have created
market leaders, from landmark historical investments including
Genentech, Actelion and Vistaprint to more recent successes such as
CoreValve, Novexel, Fovea and Sensitive Object. With a global
mindset, the firm has a sister organization in San Francisco,
California. Please visit www.sofinnova.fr for more information on
Sofinnova´s team and portfolio.

About Edmond de Rothschild Investment Partners Paris based Edmond de
Rothschild Investment Partners (EdRIP) is dedicated to minority
investments into privately owned companies. It has currently EUR750
million under management which are being invested primarily as life
sciences venture capital and growth capital. Its life science team of
seven professionals has over 90 years of cumulated experience in the
life science industry and has a proven track record in biotechnology
and medical technology investments. The team has approximately EUR270
million Euro under management, recently raised its EUR155 million
BioDiscovery 3 fund, which is to be invested during the next years.
EdRIP is part of the group Edmond de Rothschild, Paris, France. For
more information, please visit www.edrip.fr

About Seventure Being one of the leading venture capital firms in
Europe, Seventure manages EUR500m and invests since 1997 in
innovative businesses with high growth potential in Information &
Communication Technologies and in Life Sciences. The Life Sciences
team invests all over Europe. Its 4 preferred sectors are Biotech &
Pharmaceuticals, Medtech, Industrial Biotech & Cleantech, and
Lifestyle Healthcare & nutrition. A typical investment ranges from
EUR500k to EUR10 m per round, up to EUR20 m per company, from early
to later stage. Seventure is a subsidiary of Natixis Private Equity,
the asset management company of Natixis, with over EUR4.2 bn in
private equity investments. www.seventure.fr

Webseite: http://www.noxxon.com

General contact:
Emmanuelle Delabre
NOXXON Pharma AG
Max-Dohrn-Strasse 8-10
10589 Berlin, Germany
Phone: +49-30-726247-100
FAX: +49-30-726247-225
Email: edelabre@noxxon.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Deutsche Effecten- und Wechsel-Beteiligungsges. AG (DEWB)
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Marco Scheidler

Tel.: +49 (0) 3641 573-3600

E-Mail: marco.scheidler@dewb-vc.com

Branche: Financial & Business Services
ISIN: DE0008041005
WKN: 804100
Index: CDAX, Classic All Share
Börsen: Berlin / free trade
Stuttgart / free trade
München / free trade
Frankfurt / Open Market / Entry Standard